HIV-1 neutralization: Mechanisms and relevance to vaccine design

被引:41
|
作者
Zwick, Michael B. [1 ]
Burton, Dennis R. [1 ]
机构
[1] Scripps Res Inst, Dept Immunol, IMM 2, La Jolla, CA 92037 USA
关键词
neutralization mechanism; antibodies; vaccine development; virus fusion;
D O I
10.2174/157016207782418443
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Antibody (Ab) mediated neutralization is a crucial means of host resistance to many pathogens and will most likely be required in the development of a vaccine to protect against HIV-1. Here we examine mechanistic aspects of HIV-1 neutralization with attention to recent Studies on the stoichiometric, kinetic and thermodynamic parameters involved. Neutralization of HIV-1, as with any microbe, minimally requires an initial molecular encounter with Ab. Ab occupancy of functional heterotrimers of the envelope glycoproteins, gp120 and gp41 (Env), indeed appears to be the dominant mechanism of neutralization for HIV-1. However, the Ab-binding site, the parameters mentioned above, as well as the stages and duration of vulnerability to Ab recognition, prior to and leading up to viral entry, each have a distinct impact on the mechanism of neutralization for any given Ab specificity. With HIV-1, the problems of mutational variation and neutralization resistance, coupled with the lability and conformational heterogeneity in Env, have stimulated the search for rational approaches to Env immunogen design that are unprecedented in vaccinology.
引用
收藏
页码:608 / 624
页数:17
相关论文
共 50 条
  • [31] B cell immunopathology during HIV-1 infection: Lessons to learn for HIV-1 vaccine design
    Cagigi, Alberto
    Nilsson, Anna
    De Milito, Angelo
    Chiodi, Francesca
    VACCINE, 2008, 26 (24) : 3016 - 3025
  • [32] HIV-1 vaccine design through minimizing envelope metastability
    He, Linling
    Kumar, Sonu
    Allen, Joel D.
    Huang, Deli
    Lin, Xiaohe
    Mann, Colin J.
    Saye-Francisco, Karen L.
    Copps, Jeffrey
    Sarkar, Anita
    Blizard, Gabrielle S.
    Ozorowski, Gabriel
    Sok, Devin
    Crispin, Max
    Ward, Andrew B.
    Nemazee, David
    Burton, Dennis R.
    Wilson, Ian A.
    Zhu, Jiang
    SCIENCE ADVANCES, 2018, 4 (11):
  • [33] HIV-1 (co)Receptors: Implications for Vaccine and Therapy Design
    Pollakis, Georgios
    Paxton, William A.
    CURRENT PHARMACEUTICAL DESIGN, 2010, 16 (33) : 3701 - 3715
  • [34] Stabilized diverse HIV-1 envelope trimers for vaccine design
    Wang, Qian
    Ma, Bingting
    Liang, Qingtai
    Zhu, Angqi
    Wang, Hua
    Fu, Lili
    Han, Xiaoxu
    Shi, Xuanling
    Xiang, Ye
    Shang, Hong
    Zhang, Linqi
    EMERGING MICROBES & INFECTIONS, 2020, 9 (01) : 775 - 786
  • [35] Exploiting the defensive sugars of HIV-1 for drug and vaccine design
    Christopher N. Scanlan
    John Offer
    Nicole Zitzmann
    Raymond A. Dwek
    Nature, 2007, 446 : 1038 - 1045
  • [36] Editorial: New approaches to HIV-1 inhibitor and vaccine design
    Wang, Lai-Xi
    CURRENT PHARMACEUTICAL DESIGN, 2007, 13 (02) : 127 - 128
  • [37] Critical design criteria for engineering a nanoparticulate HIV-1 vaccine
    Thalhauser, Stefanie
    Peterhoff, David
    Wagner, Ralf
    Breunig, Miriam
    JOURNAL OF CONTROLLED RELEASE, 2020, 317 (317) : 322 - 335
  • [38] Exploiting the defensive sugars of HIV-1 for drug and vaccine design
    Scanlan, Christopher N.
    Offer, John
    Zitzmann, Nicole
    Dwek, Raymond A.
    NATURE, 2007, 446 (7139) : 1038 - 1045
  • [39] Multiple immune effector mechanisms as correlates of HIV-1 vaccine protection
    Heeney, JL
    Mooij, P
    Bogers, W
    Davis, D
    Morein, B
    Morghen, CD
    Lehner, T
    Voss, G
    Bruck, C
    Koopman, G
    Rosenwirth, B
    11E COLLOQUE DES CENT GARDES: RETROVIRUSES OF HUMAN AIDS AND RELATED ANIMAL DISEASES, 1998, : 281 - 285
  • [40] The HIV-1 vaccine race
    Ho, DD
    Huang, YX
    CELL, 2002, 110 (02) : 135 - 138